Why So Many People Wish They’d Found Same-Day Mounjaro Delivery Sooner
There is a conversation that happens, quietly, a few weeks into treatment.
It is not about side effects, or injection technique, or which day of the week works best. It is something simpler — and more honest. A recognition that the decision they finally made was one they could have made months, or years, earlier. That the barrier they believed was there — the complexity, the process, the waiting — turned out to be much smaller than they expected.
It is not regret about starting. It is regret about waiting.
This article is for anyone still in that waiting period. Not to pressure a decision. But to be honest about what the research says about delay — and what getting started actually involves.
What the evidence says about waiting
Weight is not a neutral state. For many people, the years spent trying to manage it through diet, exercise, and willpower alone are also years during which health risks quietly accumulate.
According to NHS England, obesity significantly increases the risk of developing several chronic conditions, including type 2 diabetes, cardiovascular disease, certain cancers, and musculoskeletal disorders, as well as being associated with reduced quality of life and increased mortality rates.
NICE guidance on overweight and obesity management notes that elevated Body Mass Index (BMI), particularly above 35, is associated with substantially increased risk of type 2 diabetes, hypertension, and cardiovascular disease — and that these risks increase progressively with BMI over time.
None of this is intended to alarm. It is intended to be honest about what the evidence actually shows — because that honesty is often absent from the conversation people have with themselves about whether to seek help.
Why people wait — and what they tell us afterwards
The reasons people delay are rarely about the treatment itself. They tend to fall into a small number of patterns.
Some people are waiting until they have tried everything else first. The implication being that prescription treatment is a last resort — something to turn to only after every other option has been exhausted. The clinical evidence does not support this framing. NICE Technology Appraisal TA1026 recommends tirzepatide as a treatment option for eligible adults — it is not a fallback for people who have failed, it is a clinically approved intervention for people who meet the criteria.
Some people assume the process will be complicated, time-consuming, or involve multiple GP appointments and referrals. In reality, a GPhC-registered online pharmacy can complete the clinical assessment, prescriber review, and same-day or next-day dispatch entirely online. For eligible patients, the gap between deciding to start and receiving treatment is often measured in days, not weeks or months.
Some people are concerned about whether it is the right decision for them personally — which is the right question to ask, and exactly what the clinical consultation is designed to answer.
What the consultation is actually for
The eligibility assessment is not a hurdle designed to catch people out. It is a clinical process designed to confirm that treatment is appropriate for you specifically — and to identify any contraindications or interactions that would make it unsafe.
NICE eligibility criteria for tirzepatide require a BMI of 30 or above, or 27 or above where weight-related health conditions are present. If you meet those criteria and have no clinical contraindications, the consultation is the beginning of treatment — not an obstacle to it.
At Together Clinic, every consultation is reviewed by a named, GPhC-registered pharmacist prescriber:
- Ahmed Nizar Al-Liabi — Superintendent Pharmacist (GPhC: 2208502)
- Sunil Thacker — Independent Pharmacist Prescriber (GPhC: 2047968)
If treatment is appropriate for you, your prescription is issued and your medication dispatched — typically within one to two working days. If it is not appropriate, you will be told clearly and directed towards an appropriate next step.
What same-day and next-day delivery actually means in practice
For many people, the discovery that prescription weight loss treatment can be accessed, assessed, and delivered within 24 to 48 hours is genuinely surprising. Not because the system is cutting corners — but because the combination of online clinical assessment, named prescriber review, and tracked cold-chain delivery has made a process that once required multiple in-person appointments genuinely accessible.
Since February 2025, the GPhC has required independent verification of patient information for all weight loss prescriptions — meaning the speed does not come at the expense of clinical rigour. A thorough assessment and fast dispatch are not in conflict.
The practical reality is that for eligible patients, the gap between deciding to start and holding a prescription in their hands is smaller than most people assume.
The cost of another month
This is not about creating urgency for its own sake. It is about being honest.
Every month of delay is another month in which the health risks associated with excess weight continue to accumulate. Another month of disrupted sleep, reduced energy, joint strain, or elevated blood pressure. Another month of managing the psychological weight of a problem that has a clinical solution.
NHS England’s interim commissioning guidance notes that obesity is associated with reduced quality of life alongside the physical health risks. That reduction in quality of life is not a footnote. For many people it is the most significant part of the experience.
The question is not whether treatment will work. The clinical evidence behind tirzepatide is well established. The question is when to start — and whether there is a good reason to wait any longer.
Frequently Asked Questions
Is it too late to start if I have been struggling with my weight for a long time? No. There is no clinical basis for the idea that treatment becomes less effective the longer you have struggled. Eligibility is assessed on current BMI and health status, not history. Your prescriber will review your individual circumstances during your consultation.
Will I need to stay on treatment indefinitely? NICE guidance recommends reviewing treatment at six months — continuing only if at least 5% of starting body weight has been lost. Long-term treatment decisions are made clinically, in discussion with your prescriber, based on your individual progress and circumstances.
What if I have tried weight loss treatments before and they did not work? Previous treatment history is part of your clinical assessment. Your prescriber will review this as part of the consultation. Tirzepatide works through a dual mechanism — activating both Glucagon-Like Peptide-1 (GLP-1) and Glucose-dependent Insulinotropic Polypeptide (GIP) receptors — which is clinically distinct from older single-mechanism treatments.
(Source: Mounjaro Summary of Product Characteristics — emc)
How quickly might I notice a difference? Individual responses to treatment vary. NICE Technology Appraisal TA1026 uses a six-month review point as the clinical benchmark — at least 5% of starting body weight lost — as the threshold for continuing treatment. Your prescriber will monitor your progress and adjust your dose accordingly.
What does the process actually involve? For a full step-by-step walkthrough from consultation to delivery, read: How Fast Is Mounjaro Delivery? What to Expect After Your Consultation.
The bottom line
The recognition that comes a few weeks into treatment — that the process was more straightforward than expected, and the decision could have been made earlier — is not universal. But it is common enough to be worth naming.
If you are eligible, the consultation is straightforward, the prescriber review is thorough, and the delivery is fast. The barrier is smaller than it may appear.
For a full overview of Mounjaro delivery in the UK, read our guide: Mounjaro Delivery UK — Everything You Need to Know Before You Order.
When you are ready to take the first step, your eligibility assessment is below.